Laura Hales, Cofounder of Extend Biosciences, spoke about her journey in biotech and entrepreneurship, and path to successfully obtaining SBIR funding on a panel on October 5. The panel was moderated by Esther Morales, Executive Director of the National Women’s Business Council, and included Barbara Fox, PhD, Marian Nakada, PhD, and Joanne Kamens, PhD. The title of the panel was “It’s All of Our Business: Succeeding as a Woman in STEM” and was part of the pre-conference to the 2016 SBIR New England Regional Summit at MIT.
News
Extend Biosciences Featured in the NSF Innovation Zone at BIO2016
Extend Biosciences was featured in the NSF Innovation Zone at the BIO International Convention 2016 in San Francisco, CA. The company received complimentary passes to the Convention, and the technology was showcased at the company’s kiosk in the Innovation Zone with a poster and a pitch presentation by CEO Tarik Soliman.
Extend Biosciences has been Awarded a Second Patent with Broad Claims
Extend Biosciences’ second patent has been awarded by the USPTO. The patent, titled “Carriers for Improved Drug Delivery” issued March 22, 2016 (US 9,289,507). The patent includes broad claims for the use of vitamin D to improve the pharmacokinetic properties of therapeutic entities.
CEO Tarik Soliman Speaks at the Peptide Showcase East Conference
Extend Biosciences’ CEO Tarik Soliman gave a talk at the Boulder Peptide Symposium’s Peptide Showcase East conference held at the Microsoft NERD Center in Cambridge, MA. The talk was titled “Harnessing the biology of vitamin D to enable sustained delivery of peptides and proteins.”
Extend Biosciences’ First Patent has been Awarded by the USPTO
Extend Biosciences’ first patent has been awarded. The patent, titled “Vitamin D-ghrelin Conjugates” issued Nov. 3, 2015 (US 9,173,940).
NIDDK Awards Extend Biosciences with a SBIR Phase I Grant for a Long-acting PTH
PTH is a key regulator of calcium and phosphorous homeostasis in the kidneys, movement of calcium from the skeleton, and the production of the active form of vitamin D in the kidneys. With this award, Extend Biosciences will be developing EXT608, a long-acting D-VITylated PTH for the treatment of hypoparathyroidism.
Extend Biosciences Featured in the Innovation Zone at the BIO2015 International Convention
Extend Biosciences was one of 12 NSF awardee companies with treatment-related technologies that was featured in the Innovation Zone at the BIO International Convention 2015 in Philadelphia, PA. The company received complimentary passes to the Convention, and the technology was showcased at the company’s kiosk in the Innovation Zone with a poster and a pitch presentation by CEO Tarik Soliman.
Extend Biosciences and LabCentral Resident Companies Featured in Science Magazine Article
Extend Biosciences and LabCentral companies Vaxess, Ymir Genomics, Advirna and others are featured in an article in Science magazine as part of a special issue on entrepreneurship. The article is titled, “Got a Startup? Rent a Bench”.
Extend Biosciences Selected to Receive MLSC MAP Grant
Extend Biosciences has been awarded a Milestone Achievement Program (MAP) grant of $200,000 from the Massachusetts Life Sciences Center. The company was one of twelve early-stage life sciences companies that was selected for an award in this new program, which was designed to provide grant funding to execute critical, value-creating technical milestones to early-stage life sciences companies.
Extend Biosciences’ Founder Laura M. Hales, Ph.D. Selected to Speak on a Biotech Entrepreneur Panel
Founder Laura M. Hales, Ph.D. spoke on a panel of women entrepreneurs at the “From Bench to Bedside: An Evening With Biotech Entrepreneurs” event sponsored by Tufts Biomedical Business Club and the Boston Entrepreneurs and Advanced Degrees Meetup Group (B.E.A.D.). The panel also featured Dr. Bonnie Fendrock (Cofounder and CEO of Cyta Therapeutics), Dr. Kathryn Kosuda (Cofounder and VP of Research and Development of Vaxess Technologies), and Cinzia Metallo (Founder and Managing Director at Biomille Technologies). The lively and interactive panel was moderated by Dr. Paulina Hill of Polaris Ventures.